Targeting ADAR1 Restores Interferon Signaling and Enhances Immunotherapy Response in Multiple Myeloma.

Songze Leng, Yaoyao Tian, Yao Liu, Weiwei Zhao, Wei Wang

Abstract read

In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Songze LengDepartment of Hematology, Second Affiliated Hospital of Harbin Medical University, Harbin 150001, China.

Yaoyao TianDepartment of Hematology, Second Affiliated Hospital of Harbin Medical University, Harbin 150001, China.

Yao LiuDepartment of Hematology, Second Affiliated Hospital of Harbin Medical University, Harbin 150001, China.

Weiwei ZhaoDepartment of Hematology, Second Affiliated Hospital of Harbin Medical University, Harbin 150001, China.

Wei WangDepartment of Hematology, Second Affiliated Hospital of Harbin Medical University, Harbin 150001, China.ORCID 0000-0002-2344-1496

Funding

a transvers research project funded by the Bei jing Huikang Charity Foundation NoneNatural Science Foundation of Hei-longjiang Province LH2022H021

6 · The paper itself

Abstract

Multiple myeloma (MM) remains an incurable hematological malignancy in which tumor-intrinsic immune evasion limits the efficacy of immunotherapy. Here, we identify the RNA editing enzyme ADAR1 as a key regulator of innate immune suppression in MM. Integrative analyses of bulk and single-cell transcriptomic datasets, together with clinical validation, demonstrated that ADAR1 is upregulated in malignant plasma cells and is associated with adverse clinical outcomes and reduced CD8

Indexed as

Adenosine DeaminaseImmunotherapyMultiple MyelomaRNA-Binding ProteinsSignal TransductionAnimalsCD8-Positive T-LymphocytesCell Line, TumorGene Expression Regulation, NeoplasticHumansInterferon-alphaInterferon-Induced Helicase, IFIH1MiceRNA EditingADAR protein, humanAdenosine DeaminaseIFIH1 protein, humanInterferon-alphaInterferon-Induced Helicase, IFIH1RNA-Binding ProteinsADAR1CD8+ T cellsIFNαMDA5multiple myeloma

Identifiers

PMID42589260

DOI10.3390/ijms27156602

PMCPMC13466300

What Socratic holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.